OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Results of Operations and Financial Condition
Item 9.01. Results of Operations and Financial Condition.
On February 26, 2019, Ophthotech Corporation announced its financial results for the quarter and year ended December 31, 2018.The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.
The information in this Form8-K (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibit relating to Item 9.01 shall be deemed to be furnished, and not filed:
Ophthotech Corp. Exhibit
EX-99 2 ophtye18earningsresultspre.htm EXHIBIT 99.1 Exhibit Ophthotech Reports Fourth Quarter and Full Year 2018 Financial and Operating Results(Conference Call and Webcast Today,…
To view the full exhibit click here
About OPHTHOTECH CORPORATION (NASDAQ:OPHT)
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.
